Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.

Nat Immunol · 2026 · PMC13132720 · PMID 41857394

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This transition was highly significant and accelerated by the booster dose, as reflected by comparing isotypes after primary (month 1) and secondary (month 19) doses within the Prime–Boost group and at month 19 between the two groups (Fig. 4a ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.